Oncotelic net loss widens to $1.9 million in Q2 FY26; revenue totals $250,000
OTLC•Operating expenses rise; cash remains limited
Operating loss widened to $2.7 million as operating expense climbed to $2.95 million, driven by higher stock-based compensation and legal fees.
Cash totaled $206,000 with working capital at a $16.45 million deficit, while management flagged substantial doubt about the company’s going-concern status.
It kept its 45% stake in GMP Bio at a $365.4 million fair value, citing no material changes since Dec. 31, 2025.
Six-month loss widens as revenue comes from Lunai services
Oncotelic posted a GAAP net loss of $1.9 million for the six months ended June 30, 2026, versus a $153,815 loss a year earlier.
Revenue was $250,000, reflecting services provided to Lunai under an IP Services Agreement.
